相关实验视频

Updated: Sep 12, 2025

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

利图西马布治疗常规疗法耐药性狼性炎:单中心体验

Esra F Senturk¹, Hande Ogun¹, Ibrahim Durucan¹

¹Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey.

Mediterranean journal of rheumatology

|August 4, 2025

概括

利图西马布显著降低了狼性炎患者的蛋白尿和疾病活性,从而降低了类固醇剂量. 这表明rituximab是治疗耐药病例的安全和有效选择.

科学领域:

腎臟病學 (nephrology) 是一種醫學專業.
类风湿病学类风湿病学
免疫学免疫学免疫学

背景情况:

抗治疗性狼性炎 (LN) 存在重大挑战和发病率.
对LN抗CD20疗法的长期结果需要进一步研究.

研究的目的:

评估Rituximab在耐火性狼性炎患者的长期疗效和安全性.
评估Rituximab对蛋白尿,功能和疾病活动标志物的影响.

主要方法:

一个单中心的回顾性研究 (2010-2022) 狼性炎患者满足SLE的ACR标准.
评估了24小时蛋白尿,肌素清除,血清肌素和Rituximab前后的SLEDAI-2K.
主要终点:普雷迪尼索隆剂量≤5mg和24小时蛋白尿 ≤500mg.

主要成果:

利图西马布治疗导致中位蛋白尿的显著减少 (3050毫克/天至747毫克/天,p<0.001).
SLEDAI-2K分数显著下降 (16.3±6.2到7.2±4.8,p<0.001). 由于这些原因,SLEEDAI-2K的分数显著下降 (16.3±6.2到7.2±4.8,p<0.001).
平均类固醇剂量从24.13±18.47mg/天减少到7.5±5.8mg/天 (p<0.001);25.5%符合两个主要终点.

结论:

利图西马布在改善疾病活性和降低耐性狼性炎中蛋白尿症方面表现出显著的疗效.
这种药物有助于大幅减少皮质类固醇需求.
利图西马布为患有耐治疗性狼性炎的患者提供了一个有前途且安全的治疗选择.

关键词:

狼性炎是一种神经炎症.这就是Rituximab.系统性红血性狼 (Systemic Lupus Erythematosus) 是一种全身性狼.

更多相关视频

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Rheumatic Heart Disease III: Medical Management

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...

Nephrotic Syndrome II : Assessment and Medical Management

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...

Chronic Kidney Disease III: Interprofessional Care

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...

Pulmonary Tuberculosis V

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...